Amplifier Therapeutics (Amplifier TX AB), is a Sweden-based biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat diseases associated with aging including metabolic conditions, cardiovascular diseases, kidney diseases, and cancer. Amplifier Therapeutics’ wholly-owned subsidiary, Betagenon AB, serves as Sponsor for the clinical trial. ATX-304 was discovered by three leading AMPK researchers: Helena Edlund, Thomas Edlund, and the late Olof Karlsson.

Isterian Biotech, a Cambrian Bio PipeCo, is a preclinical-stage biotechnology company focused on developing novel drugs to reduce or prevent excess pathological protein crosslinks from fibrotic organs for the treatment of fibrosis, and to extend healthy lifespan. The company's therapeutic agents in development target the enzyme transglutaminase (TG2), which plays a key role in protein crosslinking and in activation of TGF-β signaling.

Oviva Therapeutics, a Cambrian Bio PipeCo, is developing a first-in-class therapeutic agent targeting the AMH/AMR2 axis to extend ovarian function and improve female healthspan. Oviva’s asset is in advanced preclinical stage; this agent suppresses folliculogenesis, the process wherein follicles within the ovary – each housing a single egg – mature to ultimately ovulate. Through preservation of the ovarian reserve — the number of eggs housed in the ovaries — Oviva aims to prolong the functional lifespan of the ovary, prevent the negative health consequences that result from ovarian decline, and support systemic health in women.

Tornado Therapeutics, a Cambrian Bio PipeCo, is developing safer, more effective rapalogs to treat disease and extend healthy lifespan. Tornado’s portfolio of rapalogs includes multiple compounds that are more potent inhibitors of TORC1 and TORC2 as compared to first generation rapalogs and may have superior efficacy as compared to currently approved rapalogs in conditions such autoimmune diseases and cancer.

Vita Therapeutics, a Cambrian Bio PipeCo, is advancing a novel approach to treating a localized form of muscular dystrophy with a cell therapy that combines the power of gene correction and induced pluripotent stem cell technology. Vita utilizes iPSCs to engineer specific cell types designed to replace those that are defective in patients, focusing on two distinct methodologies to deliver these cells: an autologous approach, a patient-specific therapy; and a hypoimmunogenic approach, a universal cell designed to be used for all patients. Vita is committed to delivering long-term disease-modifying cell-engineered treatments for patients with high unmet medical needs.